Lexaria Bioscience Corp. (Nasdaq:LEXX) has reported four additional patent awards in the US, Canada and Europe. The grants cover applications involving its DehydraTECH oral drug-delivery platform and research areas related to diabetes, hypertension and epilepsy.
#US patents cover diabetes applications
US Patent 12,691,163 was granted on July 28, 2026. Lexaria said the patent covers DehydraTECH processes for GLP-1 molecules including dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide and tirzepatide.
The company identified the patent as its 3 rd US patent in Family #27, concerning compositions and methods for treating diabetes. It said the family has 5 overall granted patents, including 2 granted in Australia.
US Patent 12,758,566 was granted on October 13, 2026. It covers DehydraTECH-processed cannabidiol, or CBD, and was described by Lexaria as its 1 st patent in Family #26, also concerning compositions and methods for treating diabetes.
#Canadian and European awards
Canadian Patent 3,199,547 was granted on October 20, 2026. The patent covers DehydraTECH-processed CBD and belongs to Family #21, which relates to compositions and methods for treating hypertension.
Lexaria said this was its 1 st Canadian patent in Family #21 and its 8 th overall in the family. The family also includes 3 patents in the US, 1 in Europe, 2 in Japan and 1 in Australia.
European Patent 4522159 was published with a grant date of October 21, 2026. It covers DehydraTECH-processed CBD and forms part of Family #24, concerning compositions and methods for treating epilepsy.
According to Lexaria, the European award was its 2 nd patent in Family #24 and its 13 th overall in that family, which includes 6 in the US, 5 in Australia and 2 in Europe.
#Lexaria’s patent portfolio and platform
Lexaria said it has 70 patents granted and additional patents pending worldwide. The company operates a licensed in-house research laboratory and said its research and development programmes examine improvements in drug absorption that support intellectual-property creation and registration, as well as commercial relationships and expected revenue growth from out-licensing its technology.
DehydraTECH is Lexaria’s patented formulation and processing platform for oral drug delivery. The company says the technology is designed to improve how a range of drugs enter the bloodstream. Lexaria also says it has repeatedly shown the ability to increase bio-absorption, reduce side-effects and deliver some drugs more effectively across the blood-brain barrier.
Richard Christopher, Lexaria’s chief executive, said the company views its intellectual property as its most valuable asset. He said Lexaria had developed a patent-protected portfolio across major pharmaceutical markets and intended to continue expanding it.
#Risks and regulatory limitations
Lexaria said its forward-looking statements are estimates based on current information and involve risks and uncertainties. The company said there can be no assurance that it will achieve the plans, intentions or expectations described in those statements.
The risks identified include government regulation and regulatory approvals, the patent application and approval process, scientific discovery, competition, litigation, adverse publicity, potential adverse effects from testing or using products involving DehydraTECH, maintaining existing collaborations and realising their benefits, and delays or cancellations affecting planned research and development.
Lexaria also stated that there is no assurance that its postulated uses, benefits or advantages for patented and patent-pending technology will be realised. No statement in the release was evaluated by the Food and Drug Administration, and Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease.
#Key Takeaways
- Lexaria reported four additional patent awards in the US, Canada and Europe.
- US Patent 12,691,163 covers DehydraTECH processes for specified GLP-1 molecules.
- US Patent 12,758,566, Canadian Patent 3,199,547 and European Patent 4522159 cover DehydraTECH-processed CBD.
- The patents relate to research areas involving diabetes, hypertension and epilepsy.
- Lexaria said its portfolio includes 70 patents granted and additional patents pending worldwide, while warning that the technology’s postulated uses and benefits are not assured.
Original source: Read original article